The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors

doi:10.1016/0014-2999(86)90449-8

European Journal of Pharmacology

Volume 129, Issue 3, 7 October 1986, Pages 367-370

https://doi.org/10.1016/0014-2999(86)90449-8 Get rights and content

Abstract

The interaction of SCH 23390 with central serotonin 5-HT₂ receptors was studied in vivo on [³H]spiperone binding and in vitro on [³H]ketanserin binding. SCH 23390 inhibited [³H]spiperone binding in rat frontal cortex with an ID₅₀ of 1.5 mg/kg i.p., thus being equipotent to the two 5-HT₂ antagonists cinanserin and methysergide. In vitro, SCH 23390 competed with [³H]ketanserin with an IC₅₀ of 30 nM. These data indicate that SCH 23390 also binds with high affinity to 5-HT₂ receptors in rat brain.

References (10)

J. Arnt
Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions
Life Sci.
(1985)
S. Bischoff et al.
In vivo (³H)spiperone binding to the rat hippocampal formation: involvement of dopamine receptors
European J. Pharmacol.
(1980)
P.E. Hicks et al.
5-HT receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain
European J. Pharmacol.
(1984)
S. Bischoff
Mesohippocampal dopamine system: characterization, functional and clinical implications
A.V. Christensen et al.
Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics
Life Sci.
(1982)

There are more references available in the full text version of this article.

Cited by (242)

Acute and chronic glutamate NMDA antagonist treatment attenuates dopamine D<inf>1</inf> antagonist-induced reduction of nicotine self-administration in female rats
2024, Pharmacology Biochemistry and Behavior
Multiple interacting neural systems are involved in sustaining nicotine reinforcement. We and others have shown that dopamine D₁ receptors and glutamate NMDA receptors both play important roles in nicotine reinforcement. Blockade of D₁ receptors with the antagonist SCH-23390 (0.02 mg/kg) both acutely and chronically significantly decreased nicotine self-administration in rats. Blockade of NMDA receptors (10 mg/kg) acutely with memantine significantly increased nicotine self-administration, but chronic blockade of NMDA receptors with memantine significantly decreased nicotine self-administration. The current study examined the interactions of acute and chronic administration of SCH-23390 and memantine on nicotine self-administration in female rats. Replicating earlier studies, acute and chronic SCH-23390 significantly decreased nicotine self-administration and memantine had a biphasic effect with acute administration increasing nicotine self-administration and chronic memantine showed a non-significant trend toward decreasing it. However, chronic interaction study showed that memantine significantly attenuated the decrease in nicotine self-administration caused by chronic SCH-23390. These studies provide important information that memantine attenuates the efficacy of D₁ antagonist SCH 23390 in reducing nicotine-self-administration. These two drugs do not appear to have mutually potentiating effects to aid tobacco cessation.
Neuroleptic malignant syndrome and serotonin syndrome
2018, Handbook of Clinical Neurology
Citation Excerpt :
While some authors have advocated for the role of dopamine-1 receptors (Mechan et al., 2002), this is based on studies reporting that the dopamine-1 antagonist SCH 23390 prevents hyperthermia from MDMA. The role of dopamine-1 receptors in these studies is not clear though, as SCH 23390 is also a potent 5-HT2A receptor antagonist (Bischoff et al., 1986, 1988). Serotonin syndrome can be rapidly life-threatening and is frequently underrecognized.
The clinical manifestation of drug-induced abnormalities in thermoregulation occurs across a variety of drug mechanisms. The aim of this chapter is to review two of the most common drug-induced hyperthermic states, serotonin syndrome and neuroleptic malignant syndrome. Clinical features, pathophysiology, and treatment strategies will be discussed, in addition to differentiating between these two syndromes and differentiating them from other hyperthermic or febrile syndromes. Our goal is to both review the current literature and to provide a practical guide to identification and treatment of these potentially life-threatening illnesses. The diagnostic and treatment recommendations made by us, and by other authors, are likely to change with a better understanding of the pathophysiology of these syndromes.
Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease
2018, International Review of Neurobiology
Parkinson's disease (PD) is a neurodegenerative disease characterized by the degeneration of dopaminergic nigrostriatal connections which is recognized as the major pathophysiological event underlying the onset of motor symptoms. Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) imaging allow the study of these connections in vivo at a molecular level. Several radiotracers have been developed targeting the synthesis and metabolism of dopamine and dopaminergic receptors to investigate the nigrostriatal pathway in vivo. Molecular imaging has greatly increased our knowledge on the progression and natural history of PD, as well as the development of motor and non-motor symptoms. PET molecular imaging could be a reliable biomarker to aid earlier diagnosis and for monitoring disease progression. Furthermore, PET imaging could be used as outcome measure in the design of clinical trials testing novel pharmacological compounds aiming to slow, and ultimately halt, disease progression.
Polypharmacology of dopamine receptor ligands
2016, Progress in Neurobiology
Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson̿s disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.
Microinjections of a dopamine D1 receptor antagonist into the ventral tegmental area block the expression of cocaine conditioned place preference in rats
2014, Behavioural Brain Research
Stimulation of dopamine (DA) D1 receptors in the ventral tegmental area (VTA) is involved in primary rewards. In the current study we investigated whether VTA D1 receptor stimulation likewise plays a role in mediating the rewarding effects of cocaine-associated stimuli, using the cocaine conditioned place preference (CPP) paradigm. Rats were prepared with cannulae so as to allow microinjections in the VTA and later conditioned to a cocaine-associated environment using the CPP paradigm. Prior to each conditioning session rats were injected with either saline or cocaine (10 mg/kg, intraperitoneally) and then placed in one of the two sides of the CPP apparatus. Sessions lasted 30 min a day over a period of eight days, such that rats alternated daily between consistently experiencing cocaine in one side and saline in the other. On the test day, which was conducted one day after conditioning, rats were given bilateral microinjections of one of four doses of the D1 antagonist, SCH 23390, (0, 2, 4 or 8 μg/0.5 μl) directly into the VTA and allowed free access to both sides of the apparatus. Preference for either side was measured as time spent in each side and compared to the same measures taken before conditioning. The D1 antagonist produced a dose-related, significant reduction in the preference for the cocaine-paired side compared to vehicle. These data suggest that the expression of cocaine conditioned place preference requires stimulation of VTA D1 receptors and, as such, are the first to suggest a role for VTA dendritically released DA in cocaine-, or other reward-, related learning.
Dopaminergic modulation of the orbitofrontal cortex affects attention, motivation and impulsive responding in rats performing the five-choice serial reaction time task
2010, Behavioural Brain Research
Understanding the neurobiological factors underlying individual differences in impulsivity may provide valuable insight into vulnerability to impulse control disorders. Recent data implicate both the orbitofrontal cortex (OFC) and the dopaminergic system in psychiatric disorders associated with high levels of impulsivity, including substance abuse, mania and obsessive–compulsive disorder. However, the consequences of modulating dopaminergic activity within the OFC on impulsive behaviour are largely unknown. The effects of direct intra-OFC infusions of agonists and antagonists at the dopamine D₁ and D₂ receptors were therefore assessed in rats performing the five-choice serial reaction time test (5CSRT) of attention and motor impulsivity. Intra-OFC administration of SCH23390, a D₁ receptor antagonist, decreased impulsive responding in highly impulsive (HI) rats, but did not affect behaviour in less impulsive (LI) animals. Furthermore, the D₂ agonist quinpirole caused significant deficits in task performance, impairing accuracy, increasing omissions and decreasing the number of trials completed, which resembled the effects of systemic administration. In contrast, the D₁ agonist SKF 81297 had little effect on behaviour. Neither agonist increased impulsivity. These data provide partial support for the suggestion that high levels of impulsivity are associated with increased dopamine levels within the OFC, but further indicate that simulating dopamine's actions selectively at the D₁ or D₂ receptor cannot reproduce a highly impulsive phenotype. Dopaminergic activity within the OFC may therefore modulate impulsivity indirectly, perhaps in conjunction with other neurotransmitter systems. Furthermore, D₂-mediated neurotransmission within the OFC could make a more fundamental contribution to cognitive behaviour.

View all citing articles on Scopus

^☆: Part of this work was presented at the 6th General Meeting of the European Society of Neurochemistry, Prague, Sept. 1–6, 1986.

^∗∗: To whom all correspondence should be addressed.

^∗∗∗: J.M.S. was at CIBA-GEIGY as student.

View full text

Short communicationThe D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors☆

Abstract

Life Sci.

European J. Pharmacol.

European J. Pharmacol.

Mesohippocampal dopamine system: characterization, functional and clinical implications

Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics

Life Sci.

Short communication
The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT₂) receptors☆